This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women

This study has been completed.
Information provided by:
Novartis Identifier:
First received: December 11, 2006
Last updated: NA
Last verified: December 2006
History: No changes posted
This is a phase I study to analyze bioavailability and pharmacodynamic of two different variants of oral salmon calcitonin (SMC021) in postmenopausal women

Condition Intervention Phase
Postmenopausal Osteoporosis Drug: Oral salmon calcitonin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind, Double-Dummy, Randomized, Placebo-Controlled Crossover Phase I Study Assessing Pharmacokinetics and Pharmacodynamics of Two Different SMC021 0.8 mg Variants and the Effect of Timing of Drug Intake in Healthy Postmenopausal Women

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Pharmacokinetic profile of the new variant compared to the current variant on Day 1
  • Effect on bone resorption biomarker on Day 1

Secondary Outcome Measures:
  • Effect on bone resorption biomarker 24 hours after the last dosing on Day 3
  • Effect on bone resorption biomarker after drug intake at different timepoints
  • Effect of dosing at different timepoints on the pharmacokinetic profile

Estimated Enrollment: 86
Study Start Date: August 2006
Estimated Study Completion Date: November 2006

Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female

Inclusion Criteria:

  • Healthy postmenopausal women

Exclusion Criteria:

  • Previous treatment with other osteoporosis medication

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00411125

Copenhagen, Denmark
Sponsors and Collaborators
Study Director: Novartis Basel Novartis Basel +41 61 324 1111
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00411125     History of Changes
Other Study ID Numbers: CSMC021A2111
Study First Received: December 11, 2006
Last Updated: December 11, 2006

Keywords provided by Novartis:

Additional relevant MeSH terms:
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Salmon calcitonin
Calcitonin Gene-Related Peptide
Bone Density Conservation Agents
Physiological Effects of Drugs
Vasodilator Agents processed this record on August 22, 2017